Our vision is to provide patients with therapy-resistant cancer novel treatment options by targeting RNA-binding proteins in the spliceosome.
↓
What if... we could target cancer’s Achilles’ Heel?
Cancer is fundamentally characterized by genetic dysregulation. Spliceosome dysfunction leads to high levels of alternative RNA splicing and causes abnormal protein production. Sardona Therapeutics is therapeutically targeting RNA-binding proteins in the spliceosome that drive these oncogenic signaling pathways and therapy resistance to hit cancer’s core vulnerability: genetic instability. We believe that we can provide cancer patients with deeper and more durable treatment options.
At Sardona Therapeutics, we are pioneers in a novel area of biology that targets clinically established oncogenic pathways. With a precision oncology approach, we are advancing our initial programs with the potential to address high unmet needs in various types of metastatic cancers, including breast cancer, non-small cell lung cancer, and colorectal cancer.
Our team has built the leading drug discovery platform to target RNA binding proteins (RBPs). The platform’s foundation is Sardona’s proprietary RBP Topography Map that links different RBPs in the spliceosome to specific therapy-resistant cancers. We leverage internally developed screening assays and bioinformatics capabilities to generate novel drug candidates that target individual RBPs.
By 2030, more than 30 million people in the U.S. will have therapy-resistant cancers. We need to act boldly now and explore new approaches. That’s why Sardona Therapeutics is committed to advancing a new class of cancer therapies that have the potential to improve lives at a monumental scale.
